Expression of proto-oncogene c-kit in high risk prostate cancer

European Journal of Surgical Oncology

Volumn 30, Issue 9, 2004, Pages 987-992

  Di Lorenzo, G ^a   Autorino, R ^b,c   D'Armiento, F P ^a   Mignogna, C ^a   De Laurentiis, M ^a   De Sio, M ^b   D'Armiento, M ^a   Damiano, R ^b   Vecchio, G ^a   De Placido, S ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NONE   (Italy)

Author keywords

Adjuvant therapy; c Kit expression; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE C KIT; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTO ONCOGENE; STAINING; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION;

AGED; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR MARKERS, BIOLOGICAL;

EID: 7744229068     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2004.07.017     Document Type: Article

References (31)

1. J. Noldus J. Palisaar H. Huland Treatment of prostate cancer-the clinical use of radical prostatectomy EAU Update Ser 1 2003 16-22
2. M. Bolla Treatment of localized or locally advanced prostate cancer: The clinical use of radiotherapy EAU Update Ser 1 2003 23-31
3. M. Han A.W. Partin C.R. Pound J.I. Epstien P.C. Walsh Long term biochemical disease-free and cancer specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555-565
4. G.D. Grossfeld D.M. Stier S.C. Flanders et al. Use of second treatment following definitive local therapy for prostate cancer: Data from the CaPSURE database J Urol 160 1998 1398-1404
5. G.S. Gerber R.A. Thisted G.W. Chodak Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis Eur Urol 32 1997 385-390
6. J.I. Epstein A.W. Partin J. Sauvageot P.C. Walsh Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up Am J Surg Pathol 20 1996 286-292
7. E.M. Messing J. Manola M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer N Engl J Med 341 1999 1781-1786
8. M. Bolla Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer Eur Urol 35 1999 23-28
9. D. Kirk Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int Suppl. 86 2000 220-225
10. T. Granfors H. Modig J.E. Damber Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph-node involvement: A prospective randomized study J Urol 159 1998 2030-2035
11. A.P. Costa-Pereira T.G. Cotter Molecular and cellular biology of prostate cancer-the role of apoptosis as a target for therapy Prostate Cancer Prost Dis 1999 126-139
12. G. Di Lorenzo G. Tortora F.P. D'Armiento Expression of epidermal growth factor (EGFR) correlates with disease relapse and progression to androgen-independence in human prostate cancer Clin Cancer Res 8 2002 1-7
13. S. Signoretti R. Montironi J. Manola et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer J Natl Cancer Inst 92 2000 1918-1925
14. W.J. Huss C.F. Hanrahan R.J. Barrios J.W. Simons N.M. Greenberg Angiogenesis and prostate cancer: Identification of a molecular progression switch Cancer Res 61 2001 2736-2743
15. A. Chott S. Zijie D. Morganstern Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor Am J Pathol 155 1999 1271-1279
16. Y.-J. Ko E.J. Small F. Kabbinavar A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer Clin Cancer Res 7 2001 800-805
17. G.D. Demetri Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options Semin Oncol 28 5 Suppl. 17 2001 19-26
18. K.M. Zsebo D.A. Williams E.N. Geissler Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor Cell 63 1990 213-224
19. S. Hirota K. Isozaki Y. Moriyama Gain of function mutations of c-kit in human gastrointestinal stromal tumors Science 279 1998 577-580
20. M.C. Heinrich B.P. Rubin B.J. Longley J.A. Fletcher Biology and genetic aspects of gastrointestinal stromal tumors: Kit activation and cytogenetic alterations Hum Pathol 33 2002 484-495
21. M.J. Mauro B.J. Druker Chronic myelogenous leukaemia Curr Opin Oncol 13 2001 3-7
22. A.T. Van Oosterom I. Judson J. Verweij et al. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumors: A phase I study Lancet 358 2001 1421-1423
23. C.L. Amling E.J. Bergstralh M.L. Blute J.M. Slezak H. Zincke Defining prostate specific antigen progression after radical prostatectomy. What is the most appropriate cut point? J Urol 165 2001 1146-1151
24. P. Micke M. Basrai A. Faldum F. Bittinger L. Ronnstrand A. Blaukat Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications Clin Cancer Res 9 2003 188-194
25. E.L. Kaplan P. Meier Nonparametric estimation from incomplete observation J Am Stat Assoc 53 1958 457-481
26. D.R. Cox Regression models and life tables J Roy Stat Soc 34 1972 187-220
27. M. Roach J. Lu M.V. Pilepich et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials Int J Radiat Oncol Biol Phys 47 2000 609-615
28. R. Simak P. Capodieci D.W. Coehn et al. Expression of c-kit and kit ligand in benign and malignant prostatic tissue Histol Histopathol 15 2000 365-374
29. B.J. Drucker C.L. Sawyers H. Kantarjian Activity of a specific inhibitor of bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukaemia with the Philadelphia chromosome N Engl J Med 244 2001 1038-1042
30. H. Joensuu P.J. Roberts M. Sarlomo-Rikala Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 2001 1052-1056
31. N.M. Tiffany E.M. Wersinger M. Garzotto T.M. Beer Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer Urology 63 2004 934-939